X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SA55 Injection and Nasal Spray is a large repertoire of broad-spectrum sarbecovirus neutralizing antibodies clinical trial approved for COVID-19 infections in China.
Lead Product(s): SA55
Therapeutic Area: Infections and Infectious Diseases Product Name: SA55
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
SA55 Injection and Nasal Sprayn is a large repertoire of broad-spectrum sarbecovirus neutralizing antibodies clinical trial approved for COVID-19 infections in China.
Lead Product(s): SA55
Therapeutic Area: Infections and Infectious Diseases Product Name: SA55
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
The clinical trial will evaluate the immunogenicity and safety of one booster dose of the two candidate vaccines in adults who had received two booster doses of CoronaVac (Inactivated COVID-19 Vaccine), mRNA, or adenovirus vector COVID-19 vaccine.
Lead Product(s): Inactivated COVID-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
COVID-19 vaccine (CoronaVac/Inactivated COVID-19 Vaccine) phase III clinical studies showed vaccine has a good safety and immunogenicity profile, with no severe adverse reaction reported 6 months after two doses of vaccination among children aged 6 months to 35 months.
Lead Product(s): Inactivated COVID-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
Panflu (inactivated quadrivalent vaccine) is the first and only approved vaccine available in China against the H5N1 influenza virus, to provide protection against the H1N1 virus, also known as swine flu.
Lead Product(s): Inactivated Quadrivalent Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Anflu
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
The findings suggest that CoronaVac® has a good safety profile among the healthy pediatric and adolescent population ranging from 3 to 17 years old.
Lead Product(s): Inactivated SARS-CoV-2 Virus
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
This study includes an in-depth exploration of the immunogenic profiles of antibodies from three and two-dose CoronaVac® recipients and convalescents.
Lead Product(s): Inactivated SARS-CoV-2 virus
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2021
Details:
The approval of Sinovac’s polio vaccine (sIPV) by the NMPA in China is a major milestone in the ongoing efforts towards global polio eradication & to reduce the vaccine-associated paralytic polio caused by oral polio vaccines, which are based on live attenuated polio viruses.
Lead Product(s): sIPV
Therapeutic Area: Infections and Infectious Diseases Product Name: sIPV
Highest Development Status: Phase IIIProduct Type: Vaccine
Recipient: Intravacc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2021
Details:
According to the results of phase III clinical trial, no serious or rare adverse events were observed in relation to vaccinations, which indicates the good safety profile of SINOVAC’s sIPV vaccine.
Lead Product(s): Sabin strain based Inactivated Polio Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: sIPV
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2021
Details:
World’s first published study on clinical trial results of a Covid-19 vaccine in healthy children and adolescents aged 3 to 17 years old . CoronaVac® was found to be safe among the pediatric group aged 3 to 17 years old.
Lead Product(s): Inactivated SARS-CoV-2 virus
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
